MA26826A1 - Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba. - Google Patents

Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba.

Info

Publication number
MA26826A1
MA26826A1 MA26587A MA26587A MA26826A1 MA 26826 A1 MA26826 A1 MA 26826A1 MA 26587 A MA26587 A MA 26587A MA 26587 A MA26587 A MA 26587A MA 26826 A1 MA26826 A1 MA 26826A1
Authority
MA
Morocco
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba structural
Prior art date
Application number
MA26587A
Other languages
English (en)
Inventor
Lakhbir Singh
John Hughes
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA26826A1 publication Critical patent/MA26826A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA26587A 1999-10-07 2002-04-05 Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba. MA26826A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
MA26826A1 true MA26826A1 (fr) 2004-12-20

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26587A MA26826A1 (fr) 1999-10-07 2002-04-05 Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba.

Country Status (38)

Country Link
EP (2) EP1221950B1 (fr)
JP (2) JP2003510356A (fr)
KR (1) KR20020060192A (fr)
CN (1) CN1387434A (fr)
AP (1) AP2002002501A0 (fr)
AR (1) AR029646A1 (fr)
AT (1) ATE269072T1 (fr)
AU (2) AU7663300A (fr)
BG (1) BG106548A (fr)
BR (1) BR0014598A (fr)
CA (1) CA2385930A1 (fr)
CO (1) CO5280195A1 (fr)
CR (1) CR6614A (fr)
CZ (1) CZ20021116A3 (fr)
DE (1) DE60011650T2 (fr)
DK (1) DK1221950T3 (fr)
EA (1) EA004266B1 (fr)
EE (1) EE200200185A (fr)
ES (1) ES2220542T3 (fr)
GT (1) GT200000166A (fr)
HR (1) HRP20020286A2 (fr)
HU (1) HUP0203466A3 (fr)
IL (1) IL148965A0 (fr)
IS (1) IS6318A (fr)
MA (1) MA26826A1 (fr)
MX (1) MXPA02003484A (fr)
NO (1) NO20021625D0 (fr)
NZ (1) NZ517949A (fr)
OA (1) OA12063A (fr)
PA (1) PA8504301A1 (fr)
PE (1) PE20010708A1 (fr)
PL (1) PL357498A1 (fr)
PT (1) PT1221950E (fr)
SK (1) SK4542002A3 (fr)
TR (1) TR200200913T2 (fr)
UY (1) UY26376A1 (fr)
WO (2) WO2001024792A1 (fr)
ZA (1) ZA200202675B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
CN1720025A (zh) * 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084881A1 (fr) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODES DE TRAITEMENT DE TROUBLES INTESTINAUX FONCTIONNELS UTILISANT DES MODULATEURS DE LA SOUS-UNITE $G(A)2$G(D) DES CANAUX CALCIQUES AVEC DES MODULATEURS DES MUSCLES LISSES
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1543831A1 (fr) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CA2805371C (fr) 2010-07-30 2017-10-31 Toray Industries, Inc. Agent therapeutique ou prophylactique pour douleur neuropathique
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
DK3946260T3 (da) * 2019-03-26 2026-03-23 Orion Corp Pregabalinformuleringer og anvendelse deraf
WO2022234110A1 (fr) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Dérivés d'acide gamma-aminobutyrique destinée à être utilisée en cancérothérapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用

Also Published As

Publication number Publication date
IL148965A0 (en) 2002-11-10
HUP0203466A2 (hu) 2003-02-28
AR029646A1 (es) 2003-07-10
HRP20020286A2 (en) 2003-08-31
BR0014598A (pt) 2002-06-11
WO2001024792A1 (fr) 2001-04-12
DE60011650T2 (de) 2005-07-14
GT200000166A (es) 2002-03-30
MXPA02003484A (es) 2004-09-10
CA2385930A1 (fr) 2001-04-12
HUP0203466A3 (en) 2005-03-29
PE20010708A1 (es) 2001-07-27
AP2002002501A0 (en) 2002-06-30
DK1221950T3 (da) 2004-09-20
OA12063A (en) 2006-05-03
CO5280195A1 (es) 2003-05-30
EP1233766A1 (fr) 2002-08-28
WO2001024792A9 (fr) 2002-09-06
SK4542002A3 (en) 2003-09-11
EP1221950B1 (fr) 2004-06-16
BG106548A (en) 2002-12-29
UY26376A1 (es) 2000-12-29
JP2003510355A (ja) 2003-03-18
KR20020060192A (ko) 2002-07-16
WO2001024791A1 (fr) 2001-04-12
EP1221950A1 (fr) 2002-07-17
CZ20021116A3 (cs) 2003-05-14
NO20021625L (no) 2002-04-05
NO20021625D0 (no) 2002-04-05
PA8504301A1 (es) 2002-08-26
JP2003510356A (ja) 2003-03-18
ATE269072T1 (de) 2004-07-15
NZ517949A (en) 2003-08-29
CN1387434A (zh) 2002-12-25
CR6614A (es) 2003-12-04
PL357498A1 (en) 2004-07-26
AU7663300A (en) 2001-05-10
IS6318A (is) 2002-03-21
EA004266B1 (ru) 2004-02-26
TR200200913T2 (tr) 2002-09-23
DE60011650D1 (de) 2004-07-22
EA200200303A1 (ru) 2002-08-29
EE200200185A (et) 2003-04-15
ZA200202675B (en) 2003-04-15
PT1221950E (pt) 2004-08-31
AU1696201A (en) 2001-05-10
ES2220542T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
MA26826A1 (fr) Combinaisons synergiques d'un antagoniste recepteur de nk1 et d'un analogue structurel de gaba.
BR9612381A (pt) Antagonistas receptores vitronectina
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
BR9508178A (pt) Antagonistas de receptor de vitronectina
FR09C0028I2 (fr) ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6
DK0907364T3 (da) Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat
EP1543034A4 (fr) Traitement et prevention a l'aide d'agents fixant 4-1bb
NO993350D0 (no) Vitronectin-reseptor-antagonister
EP0828751A4 (fr) Recepteur de neuropeptides humain
ATE321784T1 (de) Pthrp analogen
ID16742A (id) Antagonis reseptor endotelin
DE69430699D1 (de) Medikamente abgebende stents
FI951300A7 (fi) Alfutsosiinihydrokloridin hitaan vapautumisen galeenisia muotoja
NO20001407D0 (no) Vitronectin-reseptor-antagonister
ITMI940039A0 (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
FR2742053B1 (fr) Compositions pharmaceutiques a base de mequitazine
FR2772272B1 (fr) Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
EP1223946A4 (fr) Recepteur humain du neuropeptide
EE04318B1 (et) Parendatud toimega LHRH antagonistid
DK1173172T3 (da) Synergistiske virkninger af amlodipin og den hydroxylerede metabolit af atorvastatin
FR2809711B1 (fr) Distributeur a organe de fixation et organe de fixation pour un tel distributeur
FR2763809B1 (fr) Forme helicoidale constituant un support de bille
KR970008209U (ko) 볼링공용 착탈식 인서트
ITMI911075U1 (it) Struttura di ancoraggio per protesi odontoiatriche su impianti endossei